Widely Prescribed Blood Pressure Drugs Linked to 33% Higher Kidney Risk in Type 2 Diabetes A recent study presented at the 63rd ERA Congress has significant implications for individuals living with type 2 diabetes.
Researchers found that patients taking dihydropyridine calcium channel blockers (DCCBs) in addition to standard therapies experienced a 33% higher risk of major adverse kidney events, including major loss of kidney filtration capacity and progression to end stage kidney disease.
The European Renal Association study followed over 31,000 adults with T2D between 2016 and 2021.